Neumora Therapeutics (NMRA) to Release Quarterly Earnings on Wednesday

Neumora Therapeutics (NASDAQ:NMRA) is projected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Neumora Therapeutics to announce earnings of ($0.23) per share for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Thursday, May 7th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.02. On average, analysts expect Neumora Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neumora Therapeutics Stock Performance

Shares of NMRA opened at $1.68 on Wednesday. The company has a market cap of $311.27 million, a price-to-earnings ratio of -1.26 and a beta of 2.74. The business’s fifty day simple moving average is $1.65 and its two-hundred day simple moving average is $2.16. Neumora Therapeutics has a 12 month low of $0.83 and a 12 month high of $3.65. The company has a current ratio of 5.09, a quick ratio of 5.09 and a debt-to-equity ratio of 0.75.

Analysts Set New Price Targets

NMRA has been the topic of a number of research analyst reports. Guggenheim reaffirmed a “buy” rating and set a $14.00 price target on shares of Neumora Therapeutics in a report on Tuesday, March 31st. Royal Bank Of Canada reduced their price objective on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Wall Street Zen lowered Neumora Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.57.

Institutional Investors Weigh In On Neumora Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC boosted its stake in shares of Neumora Therapeutics by 80.1% in the 4th quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock worth $6,474,000 after buying an additional 1,608,266 shares during the last quarter. Ikarian Capital LLC lifted its holdings in Neumora Therapeutics by 10,128.9% in the fourth quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after acquiring an additional 1,265,910 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in Neumora Therapeutics in the third quarter worth about $1,512,000. Marshall Wace LLP bought a new stake in shares of Neumora Therapeutics during the 4th quarter valued at about $1,045,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Neumora Therapeutics in the 4th quarter worth approximately $600,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.